Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 8,003 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Phase 1Phase 2 Interventional Results available

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899
Conditions
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
Interventions
Durvalumab / Tremelimumab Combination Therapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more
Completed No phase listed Observational

Veteran Health Study

NCT01175629
Conditions
Stress Disorders, Post-Traumatic, Depression, Diabetes, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Male only
Enrollment
7,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Alzheimer's Disease
Interventions
BIIB037, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
55 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Delray Beach, Florida • Orlando, Florida • Beachwood, Ohio
Conditions
Advanced Solid Tumor
Interventions
Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI), 13C,15N-Urea
Drug · Procedure
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
Interventions
DPX-E7 vaccine, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Non-small Cell Lung Cancer
Interventions
Dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Completed Phase 2 Interventional Results available

Study in Subjects Undergoing Complete Abdominoplasty

NCT03789318
Conditions
Postsurgical Pain
Interventions
CA-008 5 mg, Placebo, Bupivacaine Hydrochloride, Hydromorphone, Fentanyl, Acetaminophen, Oxycodone, CA-008 10 mg, CA-008 15 mg
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pasadena, California
Completed No phase listed Observational

Genomics of Kidney Transplantation

NCT01714440
Conditions
KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Conditions
Epilepsy Intractable
Interventions
ABI-009
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
3 Years to 26 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

NCT00824850
Conditions
Pneumococcal Conjugate Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
8 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Hayward, California • San Jose, California
Conditions
Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
Interventions
Anastrozole, Denifanstat, Exemestane, Fulvestrant, Echocardiography, Letrozole, Paclitaxel, Trastuzumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy
Drug · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
Interventions
GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi)
Drug
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
ENS-002
Biological
Lead sponsor
Concerto Biosciences
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Hollywood, Florida • Beverly, Massachusetts • Austin, Texas
Conditions
Chronic Graft vs. Host Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 120 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer, Chronic Pain, Acute Pain, Depression, Anxiety
Interventions
Questionnaires, Mechanical Temporal Summation assessment, Pain threshold assessment
Other
Lead sponsor
KK Women's and Children's Hospital
Government
Eligibility
21 Years to 80 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Advanced Solid Tumor
Interventions
SGN1
Drug
Lead sponsor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more
Conditions
Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma, Gastroesophageal Cancer (GC), Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastroesophageal Junction (GEJ) Cancer, Gastrointestinal Cancer Metastatic, Gastrointestinal Adenocarcinoma, Gastrointestinal Cancers, Colorectal (Colon or Rectal) Cancer, Pancreatic Cancer, CDH17-positive Advanced Solid Tumors, Advanced Gastric Cancer
Interventions
BHB810
Drug
Lead sponsor
BigHat Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Duarte, California • Santa Monica, California • Fairfax, Virginia
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sugar Land, Texas
Conditions
Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
Interventions
Not listed
Lead sponsor
BioCytics, Inc.
Industry
Eligibility
5 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2030
U.S. locations
1
States / cities
Huntersville, North Carolina
Conditions
Healthy Volunteers
Interventions
BGB-23339, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Pancreatic Neoplasms, Rectal Neoplasms
Interventions
Blue light, Amber light, Ambient White Light
Device · Other
Lead sponsor
Matthew Neal MD
Other
Eligibility
19 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Lymphoma, Lymphoid Hyperplasia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Solid Tumors
Interventions
GEN1079
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Lake Success, New York
Conditions
HIV-1 Infection
Interventions
Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab, Zinlirvimab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 19 more